Cargando…

Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report

RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Karino, Kohei, Fujieda, Yuichiro, Kawamura, Takuya, Abe, Nobuya, Shimoyama, Shuhei, Kono, Michihito, Kato, Masaru, Yasuda, Shinsuke, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310527/
https://www.ncbi.nlm.nih.gov/pubmed/30544475
http://dx.doi.org/10.1097/MD.0000000000013563
_version_ 1783383453138419712
author Karino, Kohei
Fujieda, Yuichiro
Kawamura, Takuya
Abe, Nobuya
Shimoyama, Shuhei
Kono, Michihito
Kato, Masaru
Yasuda, Shinsuke
Atsumi, Tatsuya
author_facet Karino, Kohei
Fujieda, Yuichiro
Kawamura, Takuya
Abe, Nobuya
Shimoyama, Shuhei
Kono, Michihito
Kato, Masaru
Yasuda, Shinsuke
Atsumi, Tatsuya
author_sort Karino, Kohei
collection PubMed
description RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma. INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the “autoimmune tumor marker” in patients with inflammatory myopathy.
format Online
Article
Text
id pubmed-6310527
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63105272019-01-14 Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report Karino, Kohei Fujieda, Yuichiro Kawamura, Takuya Abe, Nobuya Shimoyama, Shuhei Kono, Michihito Kato, Masaru Yasuda, Shinsuke Atsumi, Tatsuya Medicine (Baltimore) Research Article RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma. INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the “autoimmune tumor marker” in patients with inflammatory myopathy. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310527/ /pubmed/30544475 http://dx.doi.org/10.1097/MD.0000000000013563 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Karino, Kohei
Fujieda, Yuichiro
Kawamura, Takuya
Abe, Nobuya
Shimoyama, Shuhei
Kono, Michihito
Kato, Masaru
Yasuda, Shinsuke
Atsumi, Tatsuya
Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title_full Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title_fullStr Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title_full_unstemmed Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title_short Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
title_sort anti-tif1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310527/
https://www.ncbi.nlm.nih.gov/pubmed/30544475
http://dx.doi.org/10.1097/MD.0000000000013563
work_keys_str_mv AT karinokohei antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT fujiedayuichiro antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT kawamuratakuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT abenobuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT shimoyamashuhei antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT konomichihito antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT katomasaru antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT yasudashinsuke antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport
AT atsumitatsuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport